Original Research J Clin Psychiatry January 2023

Effect of Zuranolone on Concurrent Anxiety and Insomnia Symptoms in Women With Postpartum Depression

JCP 2023;84(1):10.4088/JCP.22m14475

Full Article Read the complete peer-reviewed article in J Clin Psychiatry. JCP 2023;84(1):10.4088/JCP.22m14475 Clinical Summary Women with postpartum depression often present with anxiety and insomnia alongside depressed mood, and these symptoms are linked to more severe illness, longer time to treatment response, impaired functioning, and increased self-harm ideation. This analysis asks whether a brief oral course of zuranolone improves that full symptom cluster quickly enough to matter in real-world postpartum care. FAQ Did zuranolone improve both depression and anxiety at the same time in women with postpartum depression? 11 questions
Key Takeaways Concurrent remission of depression and anxiety emerged rapidly with zuranolone: using HDRS-17 total score ≤ 7 plus HARS total score ≤ 7, rates were 18.9% vs 2.7% at day 3, 40.5% vs 19.2% at day 15, and 52.1% vs 23.2% at day 45. 6 takeaways Clinical Guide How should clinicians assess whether zuranolone is improving postpartum depression when anxiety and insomnia symptoms are also present? 10 steps
Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.

Insightful. Evidence-based. Human-centered.

Listen Now
The Journal of Clinical Psychiatry podcast cover with Benjamin Brody, MD

Subscribe to read
more articles

Subscribe